How much revenue did Addex Therapeutics generate this year?
Addex Therapeutics has achieved a revenue of 1.22 M CHF this year.
Addex Therapeutics Revenue 2024
Addex Therapeutics Revenue
1.22 M CHF
Ticker
ADXN.SW
ISIN
CH0029850754
WKN
A0MSH6
In 2024, Addex Therapeutics's sales reached 1.22 M CHF, a -25.69% difference from the 1.65 M CHF sales recorded in the previous year.
The Addex Therapeutics Revenue history
| YEAR | REVENUE (undefined CHF) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 7.2 | -182,95 |
| 2028e | 4.15 | -317,97 |
| 2027e | 6.91 | -190,79 |
| 2026e | 0.77 | -1722,88 |
| 2025e | 0.77 | -1722,88 |
| 2024e | 1.22 | -1076,80 |
| 2023 | 1.65 | -800,21 |
| 2022 | 1.44 | -912,14 |
| 2021 | 3.15 | -306,66 |
| 2020 | 3.88 | -167,31 |
| 2019 | 2.83 | -465,12 |
| 2018 | 6.7 | -196,64 |
| 2017 | 0.5 | -2636,58 |
| 2016 | 0.4 | -3295,33 |
| 2015 | 0.39 | -3362,07 |
| 2014 | 0.73 | -1814,00 |
| 2013 | 0.14 | -9414,29 |
| 2012 | 0.12 | -958,33 |
| 2011 | 3.74 | 13,37 |
| 2010 | 4 | -10,50 |
| 2009 | 4.5 | -21,78 |
| 2008 | 26.87 | 82,58 |
| 2007 | 0.64 | -290,63 |
| 2006 | 4.78 | 51,46 |
| 2005 | 6.15 | 66,34 |
| 2004 | 0.2 | -580,00 |
Addex Therapeutics Revenue, EBIT, Net Income CH0029850754 · A0MSH6
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Addex Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Addex Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Addex Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Addex Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Addex Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Addex Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Addex Therapeutics’s growth potential.
Addex Therapeutics Revenue, EBIT and net profit per share
| Date | Addex Therapeutics Revenue | Addex Therapeutics EBIT | Addex Therapeutics Net Income |
|---|---|---|---|
| 2029e | 7.2 M undefined | 0 undefined | 0 undefined |
| 2028e | 4.15 M undefined | -7.99 M undefined | -3.88 M undefined |
| 2027e | 6.91 M undefined | -5.82 M undefined | 0 undefined |
| 2026e | 765,000 undefined | -7.13 M undefined | -5.46 M undefined |
| 2025e | 765,000 undefined | -7.44 M undefined | -6.62 M undefined |
| 2024e | 1.22 M undefined | -5.15 M undefined | -7.12 M undefined |
| 2023 | 1.65 M undefined | -10.28 M undefined | -10.56 M undefined |
| 2022 | 1.44 M undefined | -20.52 M undefined | -20.8 M undefined |
| 2021 | 3.15 M undefined | -15.51 M undefined | -15.2 M undefined |
| 2020 | 3.88 M undefined | -12.24 M undefined | -12.86 M undefined |
| 2019 | 2.83 M undefined | -14.6 M undefined | -14.78 M undefined |
| 2018 | 6.7 M undefined | -1.42 M undefined | -1.64 M undefined |
| 2017 | 499,890 undefined | -3.24 M undefined | -3.28 M undefined |
| 2016 | 399,960 undefined | -3.14 M undefined | -3.15 M undefined |
| 2015 | 392,020 undefined | -3.04 M undefined | -4.2 M undefined |
| 2014 | 726,570 undefined | -1.8 M undefined | -1.77 M undefined |
| 2013 | 140,000 undefined | -14.46 M undefined | -14.46 M undefined |
| 2012 | 120,000 undefined | -27.01 M undefined | -27.02 M undefined |
| 2011 | 3.74 M undefined | -30.97 M undefined | -31.14 M undefined |
| 2010 | 4 M undefined | -33.6 M undefined | -33.65 M undefined |
| 2009 | 4.5 M undefined | -43.05 M undefined | -42.69 M undefined |
| 2008 | 26.87 M undefined | -24.87 M undefined | -22.07 M undefined |
| 2007 | 640,000 undefined | -37.62 M undefined | -35.09 M undefined |
| 2006 | 4.78 M undefined | -20.9 M undefined | -20.54 M undefined |
| 2005 | 6.15 M undefined | -16.4 M undefined | -16.31 M undefined |
| 2004 | 200,000 undefined | -15 M undefined | -15.05 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 200,000 CHF | -15 M CHF | -15.05 M CHF |
| 2005 | 6.15 M CHF | -16.4 M CHF | -16.31 M CHF |
| 2006 | 4.78 M CHF | -20.9 M CHF | -20.54 M CHF |
| 2007 | 640,000 CHF | -37.62 M CHF | -35.09 M CHF |
| 2008 | 26.87 M CHF | -24.87 M CHF | -22.07 M CHF |
| 2009 | 4.5 M CHF | -43.05 M CHF | -42.69 M CHF |
| 2010 | 4 M CHF | -33.6 M CHF | -33.65 M CHF |
| 2011 | 3.74 M CHF | -30.97 M CHF | -31.14 M CHF |
| 2012 | 120,000 CHF | -27.01 M CHF | -27.02 M CHF |
| 2013 | 140,000 CHF | -14.46 M CHF | -14.46 M CHF |
| 2014 | 726,570 CHF | -1.8 M CHF | -1.77 M CHF |
| 2015 | 392,020 CHF | -3.04 M CHF | -4.2 M CHF |
| 2016 | 399,960 CHF | -3.14 M CHF | -3.15 M CHF |
| 2017 | 499,890 CHF | -3.24 M CHF | -3.28 M CHF |
| 2018 | 6.7 M CHF | -1.42 M CHF | -1.64 M CHF |
| 2019 | 2.83 M CHF | -14.6 M CHF | -14.78 M CHF |
| 2020 | 3.88 M CHF | -12.24 M CHF | -12.86 M CHF |
| 2021 | 3.15 M CHF | -15.51 M CHF | -15.2 M CHF |
| 2022 | 1.44 M CHF | -20.52 M CHF | -20.8 M CHF |
| 2023 | 1.65 M CHF | -10.28 M CHF | -10.56 M CHF |
| 2024e | 1.22 M CHF | -5.15 M CHF | -7.12 M CHF |
| 2025e | 765,000 CHF | -7.44 M CHF | -6.62 M CHF |
| 2026e | 765,000 CHF | -7.13 M CHF | -5.46 M CHF |
| 2027e | 6.91 M CHF | -5.82 M CHF | 0 CHF |
| 2028e | 4.15 M CHF | -7.99 M CHF | -3.88 M CHF |
| 2029e | 7.2 M CHF | 0 CHF | 0 CHF |
Addex Therapeutics stock margins CH0029850754 · A0MSH6
The Addex Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Addex Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Addex Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Addex Therapeutics's sales revenue. A higher gross margin percentage indicates that the Addex Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Addex Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Addex Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Addex Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Addex Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Addex Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Addex Therapeutics Margin History
| Addex Therapeutics Gross margin | Addex Therapeutics Profit margin | Addex Therapeutics EBIT margin | Addex Therapeutics Profit margin |
|---|---|---|---|
| 2029e | -912.14 % | 0 % | 0 % |
| 2028e | -912.14 % | -192.84 % | -93.61 % |
| 2027e | -912.14 % | -84.28 % | 0 % |
| 2026e | -912.14 % | -932 % | -714.29 % |
| 2025e | -912.14 % | -972 % | -865.02 % |
| 2024e | -912.14 % | -420.71 % | -581.59 % |
| 2023 | -912.14 % | -624.22 % | -640.91 % |
| 2022 | -912.14 % | -1,420.12 % | -1,439.78 % |
| 2021 | -306.66 % | -491.73 % | -481.97 % |
| 2020 | -167.31 % | -315.62 % | -331.48 % |
| 2019 | -912.14 % | -515.38 % | -521.61 % |
| 2018 | -912.14 % | -21.25 % | -24.54 % |
| 2017 | -912.14 % | -647.15 % | -656.23 % |
| 2016 | -912.14 % | -785.42 % | -787.43 % |
| 2015 | -912.14 % | -775.5 % | -1,072.45 % |
| 2014 | -912.14 % | -247.28 % | -244.28 % |
| 2013 | -912.14 % | -10,328.57 % | -10,328.57 % |
| 2012 | -958.33 % | -22,508.33 % | -22,516.67 % |
| 2011 | 13.37 % | -828.07 % | -832.62 % |
| 2010 | -10.5 % | -840 % | -841.25 % |
| 2009 | -21.78 % | -956.67 % | -948.67 % |
| 2008 | 82.58 % | -92.56 % | -82.14 % |
| 2007 | -290.63 % | -5,878.13 % | -5,482.81 % |
| 2006 | 51.46 % | -437.24 % | -429.71 % |
| 2005 | 66.34 % | -266.67 % | -265.2 % |
| 2004 | -580 % | -7,500 % | -7,525 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -580 % | -7,500 % | -7,525 % |
| 2005 | 66.34 % | -266.67 % | -265.2 % |
| 2006 | 51.46 % | -437.24 % | -429.71 % |
| 2007 | -290.63 % | -5,878.13 % | -5,482.81 % |
| 2008 | 82.58 % | -92.56 % | -82.14 % |
| 2009 | -21.78 % | -956.67 % | -948.67 % |
| 2010 | -10.5 % | -840 % | -841.25 % |
| 2011 | 13.37 % | -828.07 % | -832.62 % |
| 2012 | -958.33 % | -22,508.33 % | -22,516.67 % |
| 2013 | -912.14 % | -10,328.57 % | -10,328.57 % |
| 2014 | -912.14 % | -247.28 % | -244.28 % |
| 2015 | -912.14 % | -775.5 % | -1,072.45 % |
| 2016 | -912.14 % | -785.42 % | -787.43 % |
| 2017 | -912.14 % | -647.15 % | -656.23 % |
| 2018 | -912.14 % | -21.25 % | -24.54 % |
| 2019 | -912.14 % | -515.38 % | -521.61 % |
| 2020 | -167.31 % | -315.62 % | -331.48 % |
| 2021 | -306.66 % | -491.73 % | -481.97 % |
| 2022 | -912.14 % | -1,420.12 % | -1,439.78 % |
| 2023 | -912.14 % | -624.22 % | -640.91 % |
| 2024e | -912.14 % | -420.71 % | -581.59 % |
| 2025e | -912.14 % | -972 % | -865.02 % |
| 2026e | -912.14 % | -932 % | -714.29 % |
| 2027e | -912.14 % | -84.28 % | 0 % |
| 2028e | -912.14 % | -192.84 % | -93.61 % |
| 2029e | -912.14 % | 0 % | 0 % |
Addex Therapeutics Aktienanalyse
What does Addex Therapeutics do?
Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Addex Therapeutics's Sales Figures
The sales figures of Addex Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Addex Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Addex Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Addex Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Addex Therapeutics stock
How much was the turnover of the company Addex Therapeutics compared to the previous year?
The revenue of Addex Therapeutics has increased by -25.69% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Addex Therapeutics?
The revenue of Addex Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Addex Therapeutics measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Addex Therapeutics so important for investors?
The revenue of Addex Therapeutics is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Addex Therapeutics pay?
Over the past 12 months, Addex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Addex Therapeutics is expected to pay a dividend of 0 CHF.
What is the dividend yield of Addex Therapeutics?
The current dividend yield of Addex Therapeutics is .
When does Addex Therapeutics pay dividends?
Addex Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Addex Therapeutics?
Addex Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Addex Therapeutics?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Addex Therapeutics located?
Addex Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Addex Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Addex Therapeutics from 10/27/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 10/27/2024.
When did Addex Therapeutics pay the last dividend?
The last dividend was paid out on 10/27/2024.
What was the dividend of Addex Therapeutics in the year 2023?
In the year 2023, Addex Therapeutics distributed 0 CHF as dividends.
In which currency does Addex Therapeutics pay out the dividend?
The dividends of Addex Therapeutics are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Addex Therapeutics
Our stock analysis for Addex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Addex Therapeutics Revenue
- Addex Therapeutics Net Income
- Addex Therapeutics P/E
- Addex Therapeutics P/S
- Addex Therapeutics EBIT
- Addex Therapeutics Dividend
- Addex Therapeutics Stocks
- Addex Therapeutics Market capitalization
- Addex Therapeutics Debt
- Addex Therapeutics Liabilities
- Addex Therapeutics Equity
- Addex Therapeutics AAQS
- Addex Therapeutics Employees
- Addex Therapeutics ROE
- Addex Therapeutics ROA
- Addex Therapeutics ROCE
